1Geisler JP, Sorosky JI, Duong HL, et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol, 2001, 83(3): 501-503
2Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma(UPSC): a single institution review of 129 cases. Gynecol Oncol,2003, 91(3): 463-469
3Park MH, Cho SH, Kang HI, et al. Uterine papillary serous carcinoma following radiation therapy for carcinoma of cervix: a case report.Int J Gynecol Cancer, 2000, 10(3):253-256
4Lim P, Alkushi A, Gilks B, et al. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.Cancer, 2001, 91(4): 752-757
5Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage Ⅳ uterine papillary serous carcinoma.Gynecol Oncol, 2001, 81(1): 92-99
6Bellone S, Watts K, Cane' S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol, 2005, 98(1):92-98
7Iida T, Harnano M, Yoshida N, et al. Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma. Eur J Gynecol Oncol, 2004, 25(4): 423-427
8Busmanis I, Ho TH, Tan SB, et al. p53 and bcl-2 expression in invasive and pre-invasive uterine papillary serous carcinoma and atrophic endometrium. Ann Acard Med Singapore, 2005, 34(7):421-425
9Macwhinnie N, Monaghan H. The use of p53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer,2004, 14(5):938-946
10Schmitz M J, Hendricks DT, Farley J, et al. p27 and cyclin D1 abnormalitiesin uterine papillary serous carcinoma. Gynecol Oncol, 2000, 77(3):439-445
